Unlocking the Future of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the alpha-1 antitrypsin deficiency augmentation therapy market grown in recent years?
The market size for alpha-1 antitrypsin deficiency augmentation therapy has seen considerable growth recently. It’s projected to escalate from $1.69 billion in 2024 to $1.82 billion in 2025, marking a compound annual growth rate (CAGR) of 7.3%. Reasons for this expansion during the historical period can be traced back to enhancements in diagnosis, proliferation of awareness campaigns, advances in clinical research, and an aging demographic.
How is the alpha-1 antitrypsin deficiency augmentation therapy market size expected to evolve during the forecast period?
The market size for alpha-1 antitrypsin deficiency augmentation therapy is predicted to experience robust expansion in the approaching years. By 2029, it is predicted to reach a value of $2.47 billion, achieving a 7.9% Compound Annual Growth Rate (CAGR). The anticipated growth could be attributed to advancements in telehealth, remote monitoring, precision medicine, and gene therapy. Significant trends foreseen during this period could include the availability of long-term safety and efficacy data, the use of patient-centric care models, the implementation of tele-rehabilitation programs, and the application of personalized dosing regimens.
Get your alpha-1 antitrypsin deficiency augmentation therapy market report here!
Which key drivers are propelling the alpha-1 antitrypsin deficiency augmentation therapy market’s growth?
The rise in respiratory diseases is fueling the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. These diseases, which impair lung function and lead to breathing problems, are countered by this therapy. It works by supplementing the insufficient protein in people with alpha-1 antitrypsin deficiency, bolstering protease-antiprotease activity balance in the lungs, reducing inflammation, and safeguarding lung tissue from excessive neutrophil elastase activity damage. For instance, the Centers for Disease Control and Prevention reported in March 2023 that the United States saw an increase in tuberculosis cases from 7,874 in 2021 to 8,300 in 2022. Thus, the surge in respiratory diseases is fuelling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Regarding the alpha-1 antitrypsin deficiency augmentation therapy market driver, growth is predicted to be fueled by an increase in clinical trials. Clinical trials, which are biomedical or behavioral research studies conducted on humans to answer specific questions about interventions, are important for developing and approving new AATD treatments. The rise in the number of these trials suggests an increased interest in AATD therapy development, which could bring new and more effective treatments to market. For example, in May 2023, Xtalks, a Canada-based news and information network, reported that the number of clinical studies registered on ClinicalTrials.gov had grown significantly from over 365,000 early in 2021 to 452,604 by May 2023. Consequently, the increase in clinical trials is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
What are the market segments in the alpha-1 antitrypsin deficiency augmentation therapy industry?
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –
1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp
Which leading companies are shaping the growth of the alpha-1 antitrypsin deficiency augmentation therapy market?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.
What key trends are currently impacting the alpha-1 antitrypsin deficiency augmentation therapy market’s development?
Leading firms in the acute respiratory distress syndrome (ARDS) industry are prioritizing the creation of novel therapies, such as drug development based on recombinant technology, to maintain their standing in the market. Recombinant DNA technology is utilized to create therapeutic pharmaceuticals through modification of live organisms’ DNA to produce specific proteins. For example, Inhibrx Inc., a biotechnology company situated in the US, disclosed in March 2022 that INBRX-101, a recombinant human AAT-Fc fusion protein with a potential once-monthly dosage schedule, secured an orphan drug status from the U.S. Food and Drug Administration (FDA) for the treatment of alpha-1 antitrypsin deficiency (AATD). The aim of INBRX-101 is to safely achieve and sustain the AAT levels observed in healthy persons.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006
Which geographic areas are influencing the growth of the alpha-1 antitrypsin deficiency augmentation therapy market?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024
Respiratory Disposables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
TNF Alpha Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
